<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00316745</url>
  </required_header>
  <id_info>
    <org_study_id>HGCSG0601</org_study_id>
    <secondary_id>IFOX study</secondary_id>
    <nct_id>NCT00316745</nct_id>
  </id_info>
  <brief_title>IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer</brief_title>
  <official_title>Irinotecan Combined With S-1( IRIS ) Followed by mFOLFOX6 Regimen Versus mFOLFOX6 Followed by IRIS Regimen in Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hokkaido Gastrointestinal Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hokkaido University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hokkaido Gastrointestinal Cancer Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III study compares safety and efficacy of two sequence arms in advanced
      colorectal cancer: irinotecan and S-1 (IRIS) followed by oxaliplatin containing regimen (arm
      A), or l-leucovorin (l-LV), 5-FU and oxaliplatin (mFOLFOX6) followed by irinotecan containing
      regimen (arm B).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter randomized open-label controlled phase III study is conducted in patients with
      inoperable advanced or metastatic colorectal cancer who receive no previous chemotherapy.
      Usefulness of IRIS and mFOLFOX6 regimens as the 1st-line therapy for colorectal cancer is
      evaluated in PFS, MST, incidence and severity of adverse events
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Because of approval of Bevacizumab, it was difficult to perform clinical study in 1st line
    setting.
  </why_stopped>
  <start_date>April 2006</start_date>
  <completion_date type="Anticipated">March 2009</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS of 1st line treatment</measure>
    <time_frame>2-years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>4-years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective tumor response</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS of 2nd line treatment</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>4-years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mFOLFOX6 （ → IRIS ( Irinotecan and S-1) ）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IRIS ( Irinotecan and S-1 ) → mFOLFOX6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Campto, Topotesin</intervention_name>
    <description>100 mg/m2, IV (in the vein) on day 1,15 of each cycle.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Irinotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-1</intervention_name>
    <description>S-1 Day1~14, everyday P.O.(Day 15~28 rest)</description>
    <arm_group_label>2</arm_group_label>
    <other_name>S-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Plat</intervention_name>
    <description>Oxaliplatin (85mg/m2) Day 1, 15</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Oxaliplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isovorin</intervention_name>
    <description>l-leucovorin (200mg/m2) Day 1, 15</description>
    <arm_group_label>1</arm_group_label>
    <other_name>l-leucovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>400 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle. 2400 mg/m2, CIV (in the vein) on day 1~3 (48 hours) of each 28 day cycle.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Fluorouracil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Histological diagnosis of colorectal cancer. 2） Age: 18 - 75 years. 3） No prior
        chemotherapy 4） ECOG Performance Status 0 to 2 5) A life expectancy of at least 3 months 6)
        Adequate function of major organs (bone marrow, heart, lungs, liver etc.). WBC ≧3,500/mm3
        and Neutrophil ≧2,000/mm3. Hb ≧10.0 g/dl. Platelet count ≧100,000/mm3. AST and ALT ≦2.5
        times the upper limit of normal (excluding liver metastasis). T-Bil ≦1.5 mg/dl. Creatinine
        ≦1.5 mg/ dl. 7).Patients must have the ability to understand and the willingness to sign a
        written informed contact document.

        Exclusion Criteria:

          1. Patients receiving blood transfusion, blood derivatives or granulocyte-colony
             stimulating factor within 7days prior to entering the study.

          2. Patients can not have oral intake

          3. Patients receiving Flucytosine treatment

          4. Patients with severe pleural effusion or ascites.

          5. Patients who have brown brain metastasis

          6. Patients with diarrhea 4 or more times per day

          7. Patients with active gastrointestinal bleeding.

          8. Patients with intestinal obstruction

          9. Patients with active infection.

         10. Patients with serious pulmonary disease (such as interstitial pneumonia, pulmonary
             fibrosis, pulmonary emphysema)

         11. Patients with serious complications (such as intestinal paralysis, intestinal
             obstruction, interstitial pneumonia or pulmonary fibrosis, uncontrolled diabetes
             mellitus, heart failure, renal failure, or hepatic failure).

         12. Patients with significant cardiac disease.

         13. Patients with active multiple cancer.

         14. Patients with neuropathy ≥ grade 2

         15. Patients who are pregnant, are of childbearing potential, or breast-feeding.

         16. Patients with severe mental disorder.

         17. Patients with a history of serious allergic reaction.

         18. Judged to be ineligible for this protocol by the investigation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoshito Komatsu, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hokkaido Gastrointestinal Cancer Study Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hokkaido University Hospital (Hokkaido University Graduate School of Medicine / School of Medicine)</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8638</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2006</study_first_submitted>
  <study_first_submitted_qc>April 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2006</study_first_posted>
  <last_update_submitted>October 31, 2007</last_update_submitted>
  <last_update_submitted_qc>October 31, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2007</last_update_posted>
  <keyword>irinotecan</keyword>
  <keyword>S-1</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>l-leucovorin</keyword>
  <keyword>Fluorouracil</keyword>
  <keyword>Metastatic colorectal cancer</keyword>
  <keyword>phase III</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

